Enzymotec Ltd. (NASDAQ:ENZY)’s share price dropped 4.8% during trading on Thursday . The stock traded as low as $8.27 and last traded at $8.55, with a volume of 52,212 shares. The stock had previously closed at $8.98.

ENZY has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Tuesday, April 19th. Canaccord Genuity reiterated a “hold” rating on shares of Enzymotec in a research report on Sunday, April 17th. Finally, Jefferies Group reiterated a “hold” rating on shares of Enzymotec in a research report on Wednesday, June 15th.

The stock’s 50-day moving average price is $8.33 and its 200 day moving average price is $8.51. The company has a market capitalization of $193.84 million and a PE ratio of 31.67.

Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings data on Thursday, May 19th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.04. During the same quarter in the previous year, the business posted $0.09 EPS. The company earned $14 million during the quarter, compared to analyst estimates of $13.85 million. The company’s revenue was up 23.9% on a year-over-year basis. Equities research analysts forecast that Enzymotec Ltd. will post $0.29 earnings per share for the current fiscal year.

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enable it to develop differentiated solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.